エドワーズ・ライフサイエンス・コーポレーション 外国会社臨時報告書
| 提出書類 | 外国会社臨時報告書 |
|---|---|
| 提出日 | |
| 提出者 | エドワーズ・ライフサイエンス・コーポレーション |
| カテゴリ | 外国会社臨時報告書 |
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
【表紙】
【提出書類】 外国会社臨時報告書
【提出先】 関東財務局長
【提出日】 令和元年 11 月 1 日
【会社名】 エドワーズ・ライフサイエンス・コーポレーション
(EDWARDS LIFESCIENCES CORPORATION)
【代表者の役職氏名】 最高経営責任者兼会長 マイケル・ A ・ムサレム
(Michael A. Mussallem, Chairman of the Board and Chief
Executive Officer)
アメリカ合衆国 92614 カリフォルニア州 アーバイン
【本店の所在の場所】
ワン・エドワーズ・ウェイ
(One Edwards Way, Irvine, California 92614 USA)
【代理人の氏名又は名称】 弁護士 森 下 国 彦
【代理人の住所又は所在地】 東京都千代田区大手町一丁目１番１号
大手町パークビルディング
アンダーソン・毛利・友常法律事務所
【電話番号】 03( 6775 )1000
【事務連絡者氏名】 弁護士 乙 黒 亮 祐
同 林 敬 祐
同 高 橋 祐太朗
【連絡場所】 東京都千代田区大手町一丁目１番１号
大手町パークビルディング
アンダーソン・毛利・友常法律事務所
【電話番号】 03( 6775 )1000
【縦覧に供する場所】 該当なし
( 注記 )
1. 本書において、文脈上格別に要求される場合を除き、「当社」または「エドワーズ」とは「エド
ワーズ・ライフサイエンス・コーポレーション」を指す。
2. 本書において、別段の定めがある場合を除き、「ドル」または記号「＄」は、米ドルを指す。本
書において、日本円（「 \ 」）への換算は、 2019 年 10 月 21 日現在の株式会社三菱 UFJ 銀行における対
顧客電信直売相場の仲値 1 ドル＝ 108.52 円の換算率で計算されている。
3. 本書中の表で計数が四捨五入されている場合、合計は計数の総和と必ずしも一致しない。
(Notes) :
1. In this document, the term ᰀ䌀漀洀瀀愀渀礠 or ᰀ䔀搀眀愀爀搀猠 refers to Edwards
Lifesciences Corporation unless the context requires otherwise.
1/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
2. The term ᰀ搀漀氀氀愀爀猠 or symbol ᰀ␠ in this document, unless otherwise noted,
refers to United States Dollars. In this document, conversion into Japanese Yen
("\") has been performed at the exchange rate of $1.00 = ¥ 108.52 (from the mean
of the Telegraphic Transfer Buying and Selling Exchange Rates vis-à-vis customers
in MUFG Bank, Ltd. on October 21, 2019.
3. Where figures in tables in this document have been rounded, the totals may not
necessarily equate with the sum of the figures.
2/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
１【提出理由】
当社が発行者である有価証券の募集が本邦以外の地域において開始されたため、金融商品取引
法第 24 条の 5 第 ▶ 項および第 15 項ならびに企業内容等の開示に関する内閣府令第 19 条第 1 項および第 2
項第 1 号の規定に基づき本外国会社臨時報告書を提出するものである。
２【報告内容】
(1) The primary public offering of Stock Options.
This primary public offering is regarding the grant of the Stock Options which
was made to eligible employees, contractors or directors determined pursuant to the
Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program (the
“Employee Program”) and Nonemployee Directors Stock Incentive Program (the "Directors
Program"), during the period from January 1, 2018 to December 31, 2018.
The Employee Program was initially adopted by the Board of Directors of the
Company on March 10, 2000. It was then amended and restated by the Board of Directors
of the Company on February 8, 2001, May 8, 2002, February 20, 2003, February 17, 2005,
February 16, 2006, March 6, 2007, February 14, 2008, and March 24, 2008; amended on
March 20, 2009; amended and restated on February 11, 2010; amended on March 23, 2010;
amended and restated on February 10, 2011, February 16, 2012, February 21, 2013, and
February 20, 2014; amended on November 13, 2014; and amended and restated on February
19, 2015, February 25, 2016 and February 23, 2017.
The Directors Program was initially adopted by the Board of Directors of the
Company on March 10, 2000. It was then amended and restated by the Board of Directors
of the Company on February 8, 2001, March 29, 2001, November 13, 2002, May 14, 2003,
February 19, 2004, February 17, 2005, May 12, 2005, May 10, 2007, November 13, 2008, and
February 11, 2010; amended on March 23, 2010; amended and restated on May 13, 2010;
amended on November 9, 2011; and amended and restated on February 25, 2016.
The amount of the paid-in-capital of the Company as of December 31, 2018 was
$1,384.4 million (Approx. ¥150,235 million) and the aggregate number of issued shares of
the Company was 215 million.
Primary public offering of the Stock Options
(i) Number of the Stock Options Issued
875,531
(ii) Offering Price
$0
(iii) Aggregate Amount of Offering Price
(Aggregate amount of issue price of the Stock Options)
$0
(Sum of the Aggregate amount of issue price of the Stock Options and the
aggregate Amount of the money to be paid upon exercise of the Stock
Options)
Approx. $119,388,066 (Approx. ¥12,955,992,922)
3/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
(iv) Type and Number of Shares to be Transferred upon the Exercise of the Stock
Option
(Type of Shares to be Transferred upon the Exercise of the Stock Option)
Shares of the Company’s common stock, $1.00 par value in registered
form
(Number of Shares to be Transferred upon the Exercise of the Stock Option)
875,531 Shares
(v) Amount of the Payment (per Share) upon Exercise of the Stock Options
$136.36 (Approx. ¥14,798)
This price is ▶ weighted average.
(vi) Exercise Period of the Stock Options
The exercise periods are specified on the date of grant. Generally,
the first of such exercise periods commences approximately one year
after the date of the grant, and the last exercise period ends
approximately seven years after the date of the grant.
(See “Conditions of Exercise of the Stock Options” below)
(vii) Conditions for Exercise of the Stock Options
1) Employee Program
(a) Stock Options will become exercisable in ▶ series of installments over
the vesting period. Generally, Stock Options will vest in four equal annual
installments upon the option holder’s continued employment or service over
the applicable four-year period, and will remain outstanding for seven
years measured from the grant date, unless terminated sooner upon the
option holder’s termination of employment (see Remark (c)). The actual
exercise schedule will be determined by the committee on the date of grant.
In addition, in the event of ▶ change in control (as defined in the
Program), outstanding Stock Options will immediately become vested and
exercisable for 100% of the shares under the Stock Options, unless the
Stock Options are performance-based. The Company has never granted
performance-based Stock Options.
(b) Option holders may exercise their Stock Options at any time that the
Stock Options are exercisable, provided they do so before the Stock Options
terminate.
To exercise ▶ Stock Option, the option holder must provide the Company with
notice of the exercise in ▶ form satisfactory to the Company and which
indicates the number of shares to be acquired under the Stock Option. The
notice must be accompanied with payment of the exercise price for the
acquired shares and all applicable withholding taxes or ▶ cashless exercise
notice in ▶ form satisfactory to the Company.
4/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
(c) Stock Options generally will have ▶ seven-year term, but may terminate
sooner upon certain conditions. For example, if the option holder’s
service or employment terminates, then the option holder will have ▶
limited period of time to exercise the Stock Option before it terminates.
The applicable Stock Option agreement will set forth the period during
which the option holder may exercise the Stock Option after the termination
of the employment or service.
2) Directors Program
(a) Options granted under Directors Program shall be exercisable at such
times and be subject to such restrictions and conditions as the Committee
shall in each instance approve, which need not be the same for each grant
or for each participant.
(b) Options granted under Directors Program shall be exercisable by the
delivery of ▶ written notice of exercise (or such other form of notice as
the Company may specify) to the Company, setting forth the number of Shares
with respect to which the option is to be exercised, accompanied by full
payment for the Shares (or ▶ satisfactory "cashless exercise" notice).
The option price upon exercise of any option shall be payable to the
Company in full either: (a) in cash or its equivalent; (b) by tendering
previously acquired Shares (by either actual delivery or attestation)
having an aggregate fair market value at the same time of exercise equal to
the total option price (provided that the Shares which are tendered must
have been held by the Participant for at least six 6 months, or such
shorter or longer period, if any, as is necessary to avoid variable
accounting treatment); (c) by ▶ cashless exercise as permitted under
Federal Reserve Board's Regulation T, subject to applicable securities law
restrictions and such procedures and limitations as the Company may specify
from time to time; (d) by any other means which the board determines to be
consistent with the program's purpose and applicable law; or (e) by ▶
combination of two or more of (a) through (d).
Subject to any governing rules or regulations, including cashless exercise
procedures, as soon as practicable after receipt of ▶ notification of
exercise and full payment (or ▶ satisfactory "cashless exercise" notice),
the company shall cause to be issued and delivered to the participant, in
certificate from or otherwise, evidence of the shares purchased under the
Option(s).
(viii) Amount (per Share) Capitalized on share capital if the Shares are Issued
upon the Exercise of the Stock Option
$136.36 (Approx. ¥14,798)
This price is ▶ weighted average.
(ix) Conditions of Transfer of the Stock Options
1) Employee Program
Stock Options cannot be assigned or transferred, except by the provisions
of an Option holder's will or the laws of inheritance following his/her
death.
5/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
2) Directors Program
Except as otherwise provided in ▶ participant's award agreement, no Option
granted under this plan may be sold, transferred, pledged, assigned, or
otherwise alienated or hypothecated other than by will or by the laws of
descent and distribution.
Further, except as otherwise provided in ▶ Participant's award agreement,
all Options granted to ▶ participant under this program shall be
exercisable during his or her lifetime only by such Participant.
(x) Method of issuance
Allocation for eligible employees or directors.
(xi) Name of underwriter
Not applicable.
(xii) Area of offering of the Stock Options
1) Employee Program
US, Switzerland and other multiple countries abroad
2) Directors Program
US, Switzerland and other multiple countries abroad
(xiii) Amount of net proceeds from issuance of new Stock Options and Breakdown,
Amount and Timing of Use of Proceeds
Amount of net proceeds from issuance of new Stock Options
Aggregate Amount of the Rough Estimate of the Rough Estimate of the Net
Paid in Money (Note) Expenses on the Issuance Proceeds Deducted
Approx. $119,388,066 Approx. $119,388,066
Not Applicable
(Approx. ¥12,955,992,922) (Approx. ¥12,955,992,922)
(Note) Estimated based on all Stock Options reported under this document being
granted with an exercise price of $136.36 (Approx. ¥14,798), ▶ weighted
average price for the Stock Options granted during 2018.
With regard to the matter of the expenses, the issuance is not being
delegated to ▶ third party, and there are not specific fees (e.g.,
underwriting fees) associated therewith. The issuance did generate some
internal administration expenses; however, it is difficult to allocate such
expenses appropriately.
Breakdown, Amount and Timing of Use of Proceeds
All funds received upon exercise of the Stock Options will be used for
general corporate purposes and for any other purposes as determined
from time to time. It is difficult for the Company to decide at this
stage the specific purposes and the specific amount of money allotted
for each purpose, as well as the timing of such use.
6/7
EDINET提出書類
エドワーズ・ライフサイエンス・コーポレーション(E05926)
外国会社臨時報告書
(xiv) Date of the issuance of new Stock Options
Generally, regular annual grants for existing employees and directors are
made in May each year and grants for new hires and other programs are made
from time to time.
(xv) If the relevant securities are to be listed on ▶ stock exchange, the name of
the relevant stock exchange
Not applicable.
7/7
